What Celemics does

Celemics is a Seoul-headquartered, KOSDAQ-listed (kosdaq:331920) biotechnology company founded in 2010 that develops and sells target enrichment panels and associated reagents for next-generation sequencing (NGS) workflows. Its core offering is a catalog of more than 1,000 custom-designed panels — including whole-exome, ready-to-use disease panels (e.g., CancerScreen, CancerMaster, OncoKB Plus), and bespoke designs built on proprietary probe-design, rebalancing, and molecular-barcoding chemistry — used by biopharma R&D groups, contract research organizations, clinical diagnostic laboratories, and academic research centers. Panels are validated across all major sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, and Oxford Nanopore), and the company layers in modular library-preparation kits, beads, polymerases, and capture-accessory reagents to anchor a full workflow sale.

The company monetizes primarily through direct panel and reagent sales, custom panel design services, and recurring bioinformatics subscriptions for its CAS (Celemics Analysis Service) pipeline, which performs FASTQ-to-variant calling, annotation, and clinical interpretation. A US subsidiary opened in 2024 and a strategic partnership with Strand Life Sciences extend distribution into North America and India, while product launches including the CAS Pathogen platform (2024) and an ONT Adaptive Sampling–compatible Target Enrichment Kit (May 2026) broaden the addressable workflow. The firm employs 51–100 people and has raised modest equity capital through 2026 KOSDAQ secondary offerings, consistent with a small-cap, execution-stage life-science tools company rather than an early-stage venture-backed startup.

Name

Celemics

Legal name

Celemics, Inc.

Website

https://celemics.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

51–100 employees

Short description

Celemics is a Seoul-based, KOSDAQ-listed NGS tools company that designs custom and ready-to-use target enrichment panels, library-prep reagents, and the CAS bioinformatics pipeline for biopharma, CROs, and clinical diagnostic labs globally.

Ownership category

akta.pro rank

Product category

NGS Target Enrichment Reagents and Panels

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)

SIC

Laboratory Analytical Instruments (3826), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF)

akta.pro secondary industries

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• NGS target enrichment
• Whole exome sequencing
• Companion diagnostics development
• Hybridization probe design
• Bioinformatics analysis services

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. NGS Panels and Reagents: Sale of ready-to-use NGS panels, target enrichment kits, customized panels, and modular accessories including library preparation kits, magnetic beads, hybridization enhancers, polymerases, and molecular barcode kits. Products sold directly and through distributors globally.
2. Sequencing and Bioinformatics Services: Celemics Analysis Service (CAS) providing end-to-end bioinformatics analysis from FASTQ to clinical interpretation. Also includes whole exome sequencing service, immune repertoire profiling, and high-throughput genotyping services.
3. Custom NGS Assay Development: End-to-end customized assay development from design to validation, including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and optimization for individual experiments.
4. Biopharma Solutions and Companion Diagnostics: NGS-based detection and discovery solutions for biopharma, CRO, and drug discovery research fields, including development and commercialization of companion diagnostics.
5. White-Label / OEM Products: White-labeled customized products with customer branding and labeling, allowing partners to market and sell Celemics-developed panels under their own brand for business expansion support.

Pricing tiers

Go-to-market motion2 records

Distribution channels5 records

Marketing channels6 records

Core offering

Celemics designs, manufactures, and supplies hybridization-based Next-Generation Sequencing (NGS) target enrichment panels, custom assay development services, and end-to-end bioinformatics for genomics applications in oncology, inherited disease, biopharma/CRO drug discovery, pathogen surveillance, and agrigenomics. Its offering combines proprietary probe design and rebalancing technologies, molecular barcodes for low-input and cfDNA samples, ready-to-use and customized panels, modular reagents (library prep kits, beads, polymerases), and the Celemics Analysis Service (CAS) bioinformatics pipeline running from FASTQ through clinical interpretation.

Product overview

Celemics is a biotech company specializing in NGS (Next-Generation Sequencing) solutions, offering a comprehensive portfolio of products and services organized around three core pillars: (1) Target Enrichment Products including the Whole Exome Sequencing Panel (WES, 37.1 Mb), NGS Target Enrichment Panel, Customized NGS Panel, and Ready-to-Use NGS Panels; (2) Bioinformatics through Celemics Analysis Service (CAS) providing end-to-end analysis from FASTQ to clinical interpretation; and (3) Modular Accessories including Library Preparation Kit, Double-stranded cDNA Synthesis Kit, Hybridization Enhancer, CeleMag Clean-up Beads, Streptavidin Beads, CeleNM Bead, and CLM Polymerase. The Ready-to-Use NGS Panel platform encompasses sub-brands for Somatic Cancer (CancerScreen, CancerScreen Focus, CancerMaster), Liquid Biopsy, Hereditary Cancer, BioPharma Solutions, BRCA 1/2, Clinical Exome, PharmacoScreen, Respiratory Virus, African Swine Fever Virus, High-Throughput Genotyping, RNA/Methylation/Metagenomic Sequencing, Mitochondrial DNA, and Disease Specific panels. Services include sequencing services, bioinformatics services, biopharma solutions, and custom NGS assay development. All products support multiple sequencing platforms (Illumina, MGI, Thermo Fisher, PacBio, Oxford Nanopore) and integrate with automated liquid handling systems (Hamilton, Bravo, Sciclone).

Differentiator

Problem solved

Functional benefit

Brands

• BTSeq™: Sequencing service offered by Celemics
• CancerScreen
• CancerMaster
• Celemics Analysis Service (CAS)
• CeleMag™ Clean-up Beads
• CeleNM™ Bead
• CLM Polymerase

Products and services

• Whole Exome Sequencing Panel (WES) Comprehensive whole exome panel covering 37.1 Mb target regions of all major WES panels in the market with >98% coverage, market-leading on-target ratio (>90% on gDNA and FFPE), uniformity (>96% gDNA, >95% FFPE), and up to 12-plex multiplexing, supported by the Celemics Analysis Service (CAS) bioinformatics pipeline. Targeted at clinical labs, research institutions, and biopharma doing comprehensive variant discovery across coding regions.
• NGS Target Enrichment Panel Hybridization-based target enrichment panel leveraging Celemics' proprietary probe design, rebalancing, and molecular barcode technologies to efficiently capture hard-to-capture regions, GC-rich areas, and challenging samples (damaged DNA/RNA, FFPE, ctDNA) across multiple sequencing platforms. Targeted at genomics labs running custom or research-focused capture assays.
• Customized NGS Panel End-to-end customized target enrichment panel service including custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, validation, and complete bioinformatics support, with optional white-label/OEM branding for partners. Targeted at biopharma, CROs, and research groups needing tailored assays; over 1,000 such panels have been developed and delivered globally.
• Ready-to-Use NGS Panel Pre-validated hybridization-based NGS panels covering oncology, liquid biopsy, hereditary cancer, BRCA 1/2, clinical exome, disease-specific panels, infectious disease (respiratory virus, ASFV), pharmacogenomics (PharmacoScreen), agrigenomics, RNA, methylation, metagenomic, and mitochondrial DNA sequencing applications, all built on Celemics' proprietary core technologies. Targeted at clinical and research users needing validated, ready-to-ship catalog panels.
• CancerScreen Panels Ready-to-use NGS panels for somatic cancer that detect all variant types including SNV, Indel, CNV, rearrangements, MSI, and TMB, offered in Core (13 genes), 50 (54 genes), 100 (99 genes), 400 (407 genes), and Comprehensive (706 genes) configurations. Targeted at molecular pathology and oncology labs needing comprehensive mutation profiling from FFPE or fresh tissue.
• CancerScreen Focus (CDx) Panel FDA-focused cancer panel covering major genes with coding exons concerning mutations for FDA-approved therapies, delivered in DNA (22 genes, 73.4 Kb) and RNA (9 genes, 32.1 Kb) configurations. Targeted at labs and biopharma requiring companion-diagnostic-ready content.
• CancerMaster Comprehensive somatic cancer panel detecting all variant types and immuno-oncology markers including gene rearrangements across 524 cancer-related and cancer-associated genes in a 2.5 Mb target. Targeted at advanced molecular oncology programs needing broad immuno-oncology and rearrangement profiling.
• Liquid Biopsy Panels ctDNA-based NGS panels with proprietary molecular barcodes for superior sensitivity in detecting low-frequency variants, available for lung cancer (28 genes, 47 Kb), breast cancer (27 genes, 99 Kb), and colorectal cancer (15 genes, 49 Kb). Targeted at clinical and research liquid biopsy workflows needing sensitive ctDNA variant calling.
• Hereditary Cancer (OncoRisk) Panel Comprehensive hereditary cancer panel analyzing 31 oncogenes associated with inherited cancer syndromes in a 96 Kb target. Targeted at clinical genetics and hereditary cancer screening programs.
• BRCA 1/2 Panel Comprehensive BRCA coverage panel targeting BRCA1 and BRCA2 (2 genes, 23 Kb) and covering all variant types (SNVs, indels, large rearrangements). Targeted at clinical labs offering hereditary breast/ovarian cancer testing.
• Clinical Exome Clinical exome sequencing panels for comprehensive detection of clinically significant variants, available in Standard (5,516 genes, 13.8 Mb) and Expanded (7,563 genes, 19.6 Mb) versions. Targeted at clinical diagnostics labs focused on inherited disease and rare disease variant detection.
• PharmacoScreen Pharmacogenomics panel targeting genes associated with drug metabolism, available in Standard (283 genes, 634 Kb), Epilepsy (91 genes, 575.3 Kb), and Anti-Tuberculosis (132 genes, 186.1 Kb) configurations. Targeted at clinical labs, hospitals, and biopharma running pharmacogenomics-informed prescribing.
• Disease Specific Panel Comprehensive panels for identification of 14–293 disease-related genes in a single NGS reaction with proven clinical usage, with target sizes ranging 37–1,159 Kb. Targeted at rare disease and inherited disorder diagnostic workflows.
• RNA Sequencing Panel Targeted RNA sequencing solution for transcriptome, fusion, and isoform analyses, supported by the Celemics double-stranded cDNA synthesis kit. Targeted at research and translational labs needing validated targeted RNA capture.
• Methylation Sequencing Panel Comprehensive DNA methylation sequencing solution with proprietary probes specifically designed for methyl-seq, enabling accurate detection of methylation sites for epigenetics research. Targeted at epigenetics research programs.
• Metagenomic Sequencing Panel Complete targeted metagenomic sequencing solution with flexible panel design for characterization and differentiation of microbial species and bacterial pathogen detection. Targeted at infectious disease and microbiome research labs.
• Mitochondrial DNA Panel High-uniformity, complete-coverage panel for human mitochondrial genome sequencing. Targeted at labs running mtDNA variant detection for inherited disease and population genetics research.
• Respiratory Virus Panel Comprehensive panel for rapid and accurate sequencing and identification of whole genomes of 39 respiratory virus strains in a 706 Kb target. Targeted at public health labs and infectious disease surveillance programs.
• African Swine Fever Virus Panel Accurate identification of various ASFV strains in a single NGS reaction with species-specific blockers, targeting 26 strains in a 192 Kb target. Targeted at veterinary and animal health surveillance programs.
• High-Throughput Genotyping Panel NGS-based target enrichment panel for higher genotyping efficiency and accuracy in plant and animal research, providing a cost-effective solution compared to conventional GBS, PCR, and microarray methods. Targeted at agrigenomics research and breeding programs.
• BioPharma Solutions End-to-end NGS-based detection and discovery solutions for biopharma companies, CROs, and drug discovery research fields, including companion diagnostics development, clinical trial support, drug discovery research, and pharmacogenomics panels. Targeted at biopharma and CRO drug development programs.
• Celemics Analysis Service (CAS) End-to-end bioinformatics pipeline providing primary, secondary (CNV, Large InDel, TMB, MSI detection), and tertiary (variant curation, phenotype association) analysis with a click-to-upload FASTQ workflow and automated clinical interpretation report generation. Targeted at labs needing FASTQ-to-clinical-report processing without third-party bioinformaticians.
• Immune Repertoire Profiling Service NGS-based BCR and TCR sequencing service with ultra-sensitivity MRD monitoring detecting MRD as low as 10⁻⁶, using optimized primers to minimize sequencing loss and PCR duplications. Targeted at immuno-oncology research and minimal residual disease studies.
• Whole Exome Sequencing Service Full-service WES offering using the Celemics WES panel with complete bioinformatics analysis and clinical interpretation support. Targeted at research and clinical customers needing turnkey exome sequencing without in-house wet-lab or bioinformatics capacity.
• High-Throughput Genotyping Service NGS-based target enrichment genotyping service delivering higher efficiency and accuracy than conventional GBS, PCR, and microarray methods for plant and animal research. Targeted at agrigenomics research groups and breeding programs.
• Custom NGS Assay Development Tailored-fit assay development service covering custom panel design, species-specific or sequencer-specific blockers, reagent conditioning, and validation runs to optimize individual experiments. Targeted at research and clinical customers needing non-standard or novel NGS assays.

Quantifiable outcome

• WES panel achieves >98% coverage of all exonic regions of major exome panels (37.1 Mb target size)
• +6 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability4 records

Feature7 records

Partnerships

One partnership is on record.

• Strand Life SciencescoreTechnology or Integration · 24 October 2024Strategic partnership integrating Celemics NGS target enrichment kit and bioinformatics pipeline with Strand Life Sciences' StrandOmics tertiary analysis platform. Provides seamless sample-to-report solution ensuring clinical-grade data compliance and guaranteed data residency for customers across Europe and Asia. Over 2.5 years of collaboration with Strand analyzing clinical cases including Whole Exome Sequencing for rare diseases, Hereditary Cancer Test, and OncoRisk Test for germline cancer with a 3-day turnaround time. Strand's expert variant scientists provided interpretation and review of over 30,000 variants.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Regional players

• Eurofins Genomics: Eurofins Genomics operates one of the largest global genomics service networks, offering NGS panels, custom sequencing, and bioinformatics with strong European footprint. Eurofins competes with Celemics across clinical exome, rare disease, and biopharma sequencing services, particularly in European markets.
• Azenta Life Sciences (GENEWIZ): Azenta/GENEWIZ is a major genomics services provider with global lab operations, offering NGS services including custom panels, WES, and bioinformatics. Azenta competes with Celemics' sequencing services and CAS bioinformatics offerings, particularly for biopharma customers seeking outsourcing alternatives to in-house capture workflows.

Direct peers

• Integrated DNA Technologies (IDT): IDT, owned by Danaher, is a leading provider of NGS target enrichment solutions including xGen hybridization capture panels and Lockdown probes. IDT directly competes with Celemics in custom panel development and serves the same biopharma, clinical, and research customer base with overlapping catalog offerings.
• Twist Bioscience: Twist Bioscience is the closest direct competitor to Celemics, offering DNA synthesis platforms and a comprehensive portfolio of NGS target enrichment panels and custom panels. Both companies compete in hybridization-based capture chemistry, custom panel development, and biopharma/CRO services, with Twist also pursuing the white-label/OEM model.

Broad incumbents

• Agilent Technologies: Agilent's SureSelect target enrichment platform is the dominant hybridization capture chemistry in clinical and translational genomics. Agilent competes broadly with Celemics across whole-exome, custom panels, and biopharma services, with significantly greater installed base and clinical validation footprint.
• Illumina: Illumina offers TruSeq, TruSight, and Illumina Exome panels as part of its sequencing platform ecosystem. While Illumina's capture chemistry is more limited than specialists, its bundling with the dominant sequencing platform creates competitive pressure on pure-play capture providers like Celemics, particularly in clinical genomics.
• Roche (NimbleGen): Roche's NimbleGen SeqCap capture chemistry is a legacy target enrichment platform with a substantial installed base in academic and clinical genomics. Roche competes with Celemics in whole-exome and custom capture, particularly for translational and CDx applications tied to Roche's diagnostic franchise.
• Bio-Techne: Bio-Techne's ProteinSimple and ExoDx brands include genomics-adjacent reagent and assay solutions. While Bio-Techne is more focused on proteomics, its life science tools portfolio competes for the same biopharma R&D budget and provides an alternative for reagent procurement in workflows adjacent to Celemics' products.

Emerging players

• BGI Group / MGI Tech: BGI/MGI offers an integrated sequencing platform (DNBSEQ) along with capture chemistry and panels, and Celemics explicitly validates compatibility with MGI platforms. As MGI expands internationally, it represents both a partner opportunity and a competitive threat in the broader NGS ecosystem.

Others

• Pacific Biosciences (PacBio): PacBio is a long-read sequencing platform provider with which Celemics has validated compatibility via instrument-specific blockers and assay optimization. PacBio represents both a partner (for Celemics' capture chemistry on HiFi platforms) and an indirect competitor as whole-genome HiFi sequencing reduces reliance on target enrichment.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCbeILWrF6WH1JMKkv8Hgvqg
• Facebookfacebook.com/celemics
• LinkedInlinkedin.com/company/celemics
• Instagraminstagram.com/celemics_official
• Xx.com/Celemics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celemics